|
Family reflections: George Elliott: a first-person commentary on pediatric aplastic anemia research |
Aug 2024 |
Pediatric Research |
Aplastic Anemia |
|
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
May 2024 |
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Experience of life quality from patients with aplastic anemia: a descriptive qualitative study |
Dec 2023 |
Orphanet Journal of Rare Diseases |
Aplastic Anemia |
|
Existing agents, novel agents, or transplantation for high-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Evolving therapies for lower-risk myelodysplastic syndromes |
Apr 2020 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
May 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
|
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
Feb 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
Jan 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
